Nina S. Kjellson - 30 Oct 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ Janine MacDonald, Attorney-in-Fact for Nina S. Kjellson
Issuer symbol
TYRA
Transactions as of
30 Oct 2024
Net transactions value
-$2,282,656
Form type
4
Filing time
01 Nov 2024, 18:18:43 UTC
Previous filing
31 May 2024
Next filing
06 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Sale $159,895 -9,889 -0.25% $16.17 3,926,706 30 Oct 2024 By Canaan XI L.P. F1, F2
transaction TYRA Common Stock Sale $19,225 -1,189 -0.25% $16.17 472,207 30 Oct 2024 By 2020+ Co-Investment L.P. - Series 7 F1, F3
transaction TYRA Common Stock Sale $1,471,324 -89,390 -2.3% $16.46 3,837,316 31 Oct 2024 By Canaan XI L.P. F2, F4
transaction TYRA Common Stock Sale $176,941 -10,750 -2.3% $16.46 461,457 31 Oct 2024 By 2020+ Co-Investment L.P. - Series 7 F3, F4
transaction TYRA Common Stock Sale $396,040 -23,938 -0.62% $16.54 3,813,378 01 Nov 2024 By Canaan XI L.P. F2, F5
transaction TYRA Commmon Stock Sale $10,364 -604 -0.02% $17.16 3,812,774 01 Nov 2024 By Canaan XI L.P. F2, F6
transaction TYRA Common Stock Sale $47,615 -2,878 -0.62% $16.54 458,579 01 Nov 2024 By 2020+ Co-Investment L.P. - Series 7 F3, F5
transaction TYRA Common Stock Sale $1,253 -73 -0.02% $17.16 458,506 01 Nov 2024 By 2020+ Co-Investment L.P. - Series 7 F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
F3 The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Exhibit 24.2 Power of Attorney